Traws Pharma, Inc.
Traws Pharma, Inc. (TRAW) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TRAW · as of Sep 30, 2025
Ownership Breakdown
18
Institutional Holders
▼ 1 vs Q2
$2.41M
Total Inst. Value
▲ $543,282 vs Q2
9.14M
Shares Outstanding
freeFloat 65.18%
1.30M
13F Shares Held
▲ 41,108 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TRAW largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC pharmaceutical preparations | 605.5K | 10.40% | 10.40% | $1.12B | Nov 14, 2025 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 330.0K | 5.67% | 5.67% | $610.50M | Nov 14, 2025 | — held |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 150.0K | 2.58% | 2.58% | $277.50M | Nov 14, 2025 | ▲ 200 |
VANGUARD GROUP INC pharmaceutical preparations | 87.3K | 1.50% | 1.50% | $161.43M | Nov 7, 2025 | ▲ 74.1K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 43.4K | 74.63% | 74.63% | $80.37M | Nov 12, 2025 | ▲ 7.7K |
IKARIAN CAPITAL, LLC pharmaceutical preparations | 28.5K | 48.95% | 48.95% | $52.71M | Nov 14, 2025 | — held |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 22.0K | 37.83% | 37.83% | $40.73M | Nov 14, 2025 | ▲ 6.0K |
HRT FINANCIAL LP pharmaceutical preparations | 12.6K | 21.60% | 21.60% | $23.00M | Nov 14, 2025 | NEW |
XTX TOPCO LTD pharmaceutical preparations | 10.7K | 18.40% | 18.40% | $19.81M | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 10.0K | 17.10% | 17.10% | $18.42M | Nov 12, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
6
Increased
+91.4K shares3
New Positions
first time holders1
Decreased
−3.0K shares4
Sold Out
fully exitedNet shares change (top 50)
+88.4K
+91.4K / −3.0K
Net new holders
+4
3 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TRAW insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC 10 percent owner | Apr 16, 2026 | Purchase | 1,793,187 | $1.67 | $3.00M | 1.79M | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 16, 2026 | Purchase | 597,729 | $1.67 | $998.2K | 1.20M | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 16, 2026 | Purchase | 597,729 | $1.67 | $1.00M | 597.7K | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 16, 2026 | Purchase | 597,729 | $1.67 | $1.00M | 597.7K | Form 4 ↗ |
Parker Charles Nolan Chief Financial Officer | Mar 8, 2026 | Award | 104,544 | $1.60 | $167.3K | 104.5K | Form 4 ↗ |
Parker Charles Nolan Chief Financial Officer | Dec 12, 2025 | Award | 61,571 | $2.33 | $143.5K | 61.6K | Form 4 ↗ |
Parker Charles Nolan Chief Financial Officer | Oct 12, 2025 | Award | 32,406 | $3.01 | $97.5K | 32.4K | Form 4 ↗ |
Parker Charles Nolan Chief Financial Officer | Dec 12, 2025 | Award | 15,393 | — | — | 15.4K | Form 4 ↗ |
Clarke Trafford director | Mar 8, 2026 | Award | 33,435 | $1.60 | $53.5K | 33.4K | Form 4 ↗ |
CAUTREELS WERNER director | Mar 8, 2026 | Award | 31,258 | $1.60 | $50.0K | 31.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Traws Pharma, Inc. (TRAW) is primarily owned by institutional investors, who hold approximately 14.3% of total shares outstanding. Company insiders own approximately 34.82%, while retail and public investors account for the remaining 50.91%.
The largest institutional shareholder of Traws Pharma, Inc. is ORBIMED ADVISORS LLC, holding approximately 605,531 shares — equal to 10.40% of outstanding shares — as of September 30, 2025.
A total of 18 institutional investors currently hold TRAW stock, with a combined institutional value of approximately $2,413,244 as of the most recent 13F filing period.
Frequently asked questions
TRAW ownershipTraws Pharma, Inc. (TRAW) is primarily owned by institutional investors, who hold approximately 14.3% of shares. The largest shareholder is ORBIMED ADVISORS LLC with a 10.40% stake. Company insiders hold 34.82%. Data sourced from SEC Form 13F as of September 30, 2025.